Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPARK: Safety and Efficacy of Low Dose Radiotherapy Combined With Sintilimab and Platinum Based Chemotherapy as Neoadjuvant Therapy for Stage II-III Non-Small Cell Lung Cancer

NCT06714708 is registered in ClinicalTrials.gov with Anhui Provincial Cancer Hospital as lead sponsor.

NCT NCT06714708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06714708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPARK: Safety and Efficacy of Low Dose Radiotherapy Combined With Sintilimab and Platinum Based Chemotherapy as Neoadjuvant Therapy for Stage II-III Non-Small Cell Lung Cancer
Lead sponsor
Anhui Provincial Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 20, 2024
Completion date
June 1, 2027
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

low dose radiotherapy, neoadjuvant immunotherapy, nsclc, sintilimab